Reata Pharmaceuticals — Technical Presentation (June 2017)
23 slides from Reata Pharmaceuticals's technical presentation, Jun 2, 2017
Slide 1: Safety, Efficacy, and Pharmacodynamics of Omav in Friedreich's Ataxia Patients (MOXIe): Part 1 Results
Safety, Efficacy, and Pharmacodynamics of Omav (Omaveloxolone) in Friedreich’s Ataxia Patients (MOXIe Trial): Part 1 Results June 2, 2017 Lynch, D.1; Farmer, J.2; Meyer, C.3; Boesch, S.4; Chin, M.3; Delatycki, M.5; Giunti, P.6; Goldsberry, A.3; Hoyle, C.7; McBride, M.1; O’Grady, M.3; Perlman, S.8; S
Slide 2: Overview of Friedreich's Ataxia
Overview of Friedreich’s Ataxia FA is a progressive and life-shortening neuromuscular disorder Caused by mutations in frataxin Associated with loss of coordination and ambulation, fatigue, and metabolic disturbances No approved treatments Friedreich’s Ataxia Rating Scale (FARS) measures disease seve
Slide 3: Nrf2 and Mitochondria are Dysregulated in FA
Nrf2 and Mitochondria are Dysregulated in FA Nrf2 is suppressed in FA and contributes to oxidative stress, mitochondrial dysfunction and reduced ATP production Reduced nuclear expression of Nrf2 Reduced levels of glutathione and antioxidant Nrf2 target genes In FA patients, mitochondrial function (o
Slide 4: Omav Induces Nrf2 and Restores Mitochondrial Function
Omav Induces Nrf2 and Restores Mitochondrial Function In cultured muscle and FA cells, Omav: Induces Nrf2 as measured by Nrf2 target NQO1 Increases mitochondrial function as measured by ATP levels and transmembrane potential Dose-response shows dose-dependent increases followed by plateau and then a
Slide 5: MOXIe Study Design
MOXIe Study Design MOXIe designed as a two-part study Part 1 designed to assess multiple endpoints across a range of doses Part 2 designed to confirm efficacy and safety Part 1: Phase 2, double-blind, randomized, placebo-controlled, dose-ranging, multi-center, international trial Cohorts of 8 patien
Slide 6: MOXIe Objectives
MOXIe Objectives Key questions to answer from Part 1 of MOXIe: Does Omav induce Nrf2 in FA patients? Does Nrf2 induction translate to improvements of metabolism and mitochondrial function? What is the optimal dose for induction of Nrf2 and improvements in pharmacodynamic markers? Does Omav improve a
Slide 7: Patient Disposition
Patient Disposition Patients were randomized 3:1 across 7 dose levels in cohorts of 8 patients 2 cohorts were enrolled at 160 mg (12 Omav and 4 Pbo) 2 cohorts were enrolled at 300 mg with final cohort enrolling 5 patients (10 Omav and 3 Pbo) Omav was well-tolerated with a single discontinuation in a
Slide 8: Baseline Characteristics
Baseline Characteristics Total of 69 patients were enrolled Baseline characteristics were generally balanced across treatment groups Average age upon study entry of 25.6 years Average age at diagnosis of 15.3 years 90% of patients ambulatory Mean modified FARS of 41.1 Placebo Omav All N 17 52 69 Fem
Slide 9: Omav Dose-Dependently Increases Nrf2 Targets
Omav Dose-Dependently Increases Nrf2 Targets Several Nrf2 targets, including ferritin and GGT, were routinely monitored Dose-dependent Nrf2 activation observed with Omav Robust changes observed at 80 - 300 mg Ferritin GGT a Change from baseline comparison to zero and LSMEAN estimates at Week 4 using
Slide 10: Omav Improves Markers of Metabolism and Mitochondrial Function
Omav Improves Markers of Metabolism and Mitochondrial Function Aspartate transaminase (AST) and creatine kinase (CK) are indirectly regulated by Nrf2 and are indicative of improved metabolism AST delivers substrates for energy production to the mitochondria as part of malate shuttle Improvements in
Slide 11: Dose-Dependent Improvements in mFARS
Dose-Dependent Improvements in mFARS Omav significantly improved mFARS from baseline across all doses (p<0.001) Generally dose-dependent improvements by Week 12 that are maximal at 160 mg Placebo-corrected change at 160 mg (-2.3) neared statistical significance (p=0.06) and equivalent to ~1 year of
Slide 12: Pharmacodynamic Changes Associated with Efficacy Improvements
Pharmacodynamic Changes Associated with Efficacy Improvements mFARS changes mirrored AST induction, as well as in vitro NQO1 and ATP changes PD and efficacy responses more robust and maximal at doses of 80 – 160 mg Reduced activity at 300 mg Subsequent data presentations focused on doses associated
Slide 13: Time Dependent Improvements in mFARS
Time Dependent Improvements in mFARS mFARS improved at Week 4 and further increased by Week 12 At Omav 160 mg, large mFARS improvements are observed as early as Week 4 a Change from baseline comparison to zero and LSMEAN estimates at Week 12 using mixed-model repeated measures
Slide 14: mFARS Change More Robust in Patients without Musculoskeletal Foot Deformity
mFARS Change More Robust in Patients without Musculoskeletal Foot Deformity Patients who present with FA while growing can develop a musculoskeletal foot deformity that causes high arched feet and is called pes cavus Presence of foot deformity does not affect placebo change in mFARS Placebo-correcte
Slide 15: Cumulative Distribution Shows Broad Changes in mFARS
Cumulative Distribution Shows Broad Changes in mFARS mFARS data demonstrate greater magnitude improvements for Omav-treated patients Presence of foot deformity identified patients less likely to respond Absence of foot deformity identified patients more likely to respond Omav 80 – 160 mg Individual
Slide 16: Summary of Exercise Testing Results
Summary of Exercise Testing Results No difference in peak work versus placebo Received reports from clinical sites that some patients with foot deformity were unable to reach peak muscle exhaustion due to foot pain Analyzed data to better understand the effect of foot deformity on exercise testing r
Slide 17: Peak Work Improved in Patients without Foot Deformity
Peak Work Improved in Patients without Foot Deformity Time-dependent improvements in peak workload in patients without foot deformity that were maximal at 160 mg 16% improvement in peak workload in 160 mg patients vs. 3% improvement in placebo patients without foot deformity (13% relative improvemen
Slide 18: Additional Efficacy Measures: 25-ft Walk Test
Additional Efficacy Measures: 25-ft Walk Test Omav-treated patients showed a numerical improvement in 25-ft walk test versus placebo Results more robust in patients without musculoskeletal foot deformity Results neared statistical significance at 80 – 160 mg Omav 80 – 160 mg Individual 25-ft Walk Ti
Slide 19: Pharmacokinetics
Pharmacokinetics PK demonstrated generally dose-dependent and linear increases in exposure Cmax at 300 mg is in the concentration range where decreased Nrf2 induction and mitochondrial function were observed in vitro Cmax Dose, mg (n) Tmaxa (hr) Cmaxb (ng/mL) AUC(0-24hr) b (hr*ng/mL) 2.5 (6) 2 2.20
Slide 20: Adverse Events
Adverse Events Adverse events were generally mild in severity Increased upper respiratory tract infections and nasopharyngitis, which were generally mild in severity ALT and AST increases are expected pharmacological effects of Nrf2 activation and were not associated with any signs or symptoms of li
Slide 21: Summary of Part 1 Data
Summary of Part 1 Data Time-dependent and dose-dependent changes in PD and efficacy assessments most robust at 80 to 160 mg Omav dose (mg)a 5 10 20 40 80 160 300 Number of patients 6 6 6 6 6 12 10 Nrf2 induction in FA patients Ferritin ü ü ü GGT ü ü ü Improved PD markers of metabolism and mitochondr
Slide 22: MOXIe Part 2 Study Design
MOXIe Part 2 Study Design Key Design Elements of Part 2 Endpoints Primary: mFARS Secondary: peak work Exploratory: activities of daily living (ADL), 25-foot timed walk test, 9-hole peg test, frequency of falls, SF-36 Dose Patients randomized 1:1 (150 mg Omav : PBO) Stratification by presence or abse
Slide 23: Thanks to all investigators, site personnel and patients
Thanks to all investigators, site personnel, data safety monitoring committee members, FARA and patients who participated in the design, conduct, and analysis of MOXIe
Reata Pharmaceuticals — Technical Presentation (June 2017) on 6ix